Cefotiam


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Susceptible infections; Surgical prophylaxis 200-400 mg bid. IV/IM Susceptible infections; Surgical prophylaxis As HCI: Up to 6 g/day in divided doses. As hexetil HCl: 200-400 mg bid.
Dosage Details
Oral
Prophylaxis of surgical infections, Susceptible infections
Adult: 200-400 mg bid.

Parenteral
Prophylaxis of surgical infections, Susceptible infections
Adult: As hydrochloride: Up to 6 g daily IV/IM in divided doses according to severity of infection. As hexetil hydrochloride: 200-400 mg bid.
Renal Impairment
Parenteral:
Dose reduction may be needed.
Administration
Should be taken with food. Take just before meals.
Contraindications
Hypersensitivity to cephalosporins.
Special Precautions
Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status. May cause bleeding (reversible with vitamin K admin).
Adverse Reactions
Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction; haematologic disorders; pain at Inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.
Potentially Fatal: Pseudomembranous colitis.
Drug Interactions
Disulfiram-like interaction with alcohol. May enhance hypoprothrombinaemic response to anticoagulants. Renal clearance reduced by probenecid.
Lab Interference
Positive direct antiglobulin Coombs' test; falsely high values with Jaffe method of measuring creatinine concentrations; +ve reactions for false glucose using copper-reduction reactions; transient increases in liver enzyme values.
Action
Description: Cefotiam inhibits final cross-linking stage of peptidoglycan production thus inhibiting bacterial cell wall synthesis. It has similar or less activity against gm+ve staphylococci and streptococci, but is resistant to some β-lactamases produced by gm-ve bacteria. It is more active against many of the Enterobacteriaceae including Enterobacter, E. coli, Klebsiella, Salmonella and indole-positive Proteus sp.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cefotiam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in